132 related articles for article (PubMed ID: 33127326)
1. The Role of Hypertension and Renin-angiotensin-aldosterone System Inhibitors in Bleomycin-induced Lung Injury.
Hara R; Onizuka M; Shiraiwa S; Harada K; Aoyama Y; Ogiya D; Toyosaki M; Suzuki R; Machida S; Ohmachi K; Ogawa Y; Kawada H; Watanabe S; Miyajima A; Masuda R; Iwazaki M; Mikami M; Koike T; Mochizuki H; Ando K
Clin Lymphoma Myeloma Leuk; 2021 Apr; 21(4):e321-e327. PubMed ID: 33127326
[TBL] [Abstract][Full Text] [Related]
2. Impact of renin-angiotensin-aldosterone blockade by angiotensin-converting enzyme inhibitors or AT-1 blockers on frequency of contrast medium-induced nephropathy: a post-hoc analysis from the Dialysis-versus-Diuresis (DVD) trial.
Kiski D; Stepper W; Brand E; Breithardt G; Reinecke H
Nephrol Dial Transplant; 2010 Mar; 25(3):759-64. PubMed ID: 19903660
[TBL] [Abstract][Full Text] [Related]
3. Renin-angiotensin-aldosterone system inhibitors and the risk of mortality in patients with hypertension hospitalised for COVID-19: systematic review and meta-analysis.
Ssentongo AE; Ssentongo P; Heilbrunn ES; Lekoubou A; Du P; Liao D; Oh JS; Chinchilli VM
Open Heart; 2020 Nov; 7(2):. PubMed ID: 33154144
[TBL] [Abstract][Full Text] [Related]
4. RAAS inhibitors are not associated with mortality in COVID-19 patients: Findings from an observational multicenter study in Italy and a meta-analysis of 19 studies.
COVID-19 RISk and Treatments (CORIST) Collaboration
Vascul Pharmacol; 2020 Dec; 135():106805. PubMed ID: 32992048
[TBL] [Abstract][Full Text] [Related]
5. Renin Angiotensin Aldosterone System Inhibitors in Hypertension: Is There Evidence for Benefit Independent of Blood Pressure Reduction?
Bavishi C; Bangalore S; Messerli FH
Prog Cardiovasc Dis; 2016; 59(3):253-261. PubMed ID: 27777044
[TBL] [Abstract][Full Text] [Related]
6. Renin-angiotensin-aldosterone-system inhibition is safe in the preoperative period surrounding carotid endarterectomy.
Steely AM; Callas PW; Bertges DJ;
J Vasc Surg; 2016 Mar; 63(3):715-21. PubMed ID: 26603543
[TBL] [Abstract][Full Text] [Related]
7. Race, obesity, and the renin-angiotensin-aldosterone system: treatment response in children with primary hypertension.
South AM; Arguelles L; Finer G; Langman CB
Pediatr Nephrol; 2017 Sep; 32(9):1585-1594. PubMed ID: 28411317
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of the renin angiotensin aldosterone system: focus on aliskiren.
Rao MS
J Assoc Physicians India; 2010 Feb; 58():102-8. PubMed ID: 20653151
[TBL] [Abstract][Full Text] [Related]
9. Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin-angiotensin-aldosterone system inhibitors involving 158,998 patients.
van Vark LC; Bertrand M; Akkerhuis KM; Brugts JJ; Fox K; Mourad JJ; Boersma E
Eur Heart J; 2012 Aug; 33(16):2088-97. PubMed ID: 22511654
[TBL] [Abstract][Full Text] [Related]
10. Renin-Angiotensin Aldosterone System Inhibitors in Primary Prevention and COVID-19.
Loader J; Lampa E; Gustafsson S; Cars T; Sundström J
J Am Heart Assoc; 2021 Aug; 10(15):e021154. PubMed ID: 34320843
[TBL] [Abstract][Full Text] [Related]
11. Effect of renin-angiotensin-aldosterone system inhibitors on Covid-19 patients in Korea.
Park J; Lee SH; You SC; Kim J; Yang K
PLoS One; 2021; 16(3):e0248058. PubMed ID: 33705440
[TBL] [Abstract][Full Text] [Related]
12. Association of Renin-angiotensin-aldosterone System Inhibitors With Coronavirus Disease 2019 (COVID-19)- Related Outcomes in Korea: A Nationwide Population-based Cohort Study.
Jung SY; Choi JC; You SH; Kim WY
Clin Infect Dis; 2020 Nov; 71(16):2121-2128. PubMed ID: 32442285
[TBL] [Abstract][Full Text] [Related]
13. Incidence of and risk factors for severe acute kidney injury in children with heart failure treated with renin-angiotensin system inhibitors.
Terano C; Ishikura K; Miura M; Hamada R; Harada R; Sakai T; Hamasaki Y; Hataya H; Ando T; Honda M
Eur J Pediatr; 2016 May; 175(5):631-7. PubMed ID: 26687571
[TBL] [Abstract][Full Text] [Related]
14. Resistant Hypertension On Treatment (ResHypOT): sequential nephron blockade compared to dual blockade of the renin-angiotensin-aldosterone system plus bisoprolol in the treatment of resistant arterial hypertension - study protocol for a randomized controlled trial.
Cestário EDES; Fernandes LAB; Giollo-Júnior LT; Uyemura JRR; Matarucco CSS; Landim MIP; Cosenso-Martin LN; Tácito LHB; Moreno H; Vilela-Martin JF; Yugar-Toledo JC
Trials; 2018 Feb; 19(1):101. PubMed ID: 29433578
[TBL] [Abstract][Full Text] [Related]
15. Potassium homeostasis and renin-angiotensin-aldosterone system inhibitors.
Weir MR; Rolfe M
Clin J Am Soc Nephrol; 2010 Mar; 5(3):531-48. PubMed ID: 20150448
[TBL] [Abstract][Full Text] [Related]
16. Update on association between exposure to renin-angiotensin-aldosterone system inhibitors and coronavirus disease 2019 in South Korea.
Seo J; Son M
Korean J Intern Med; 2021 Mar; 36(Suppl 1):S114-S122. PubMed ID: 32872736
[TBL] [Abstract][Full Text] [Related]
17. Renin-angiotensin-aldosterone system blockade effects on the kidney in the elderly: benefits and limitations.
Turgut F; Balogun RA; Abdel-Rahman EM
Clin J Am Soc Nephrol; 2010 Jul; 5(7):1330-9. PubMed ID: 20498247
[TBL] [Abstract][Full Text] [Related]
18. Hypertension: renin-angiotensin-aldosterone system alterations.
Te Riet L; van Esch JH; Roks AJ; van den Meiracker AH; Danser AH
Circ Res; 2015 Mar; 116(6):960-75. PubMed ID: 25767283
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the treatment gap between clinical guidelines and the utilization of renin-angiotensin-aldosterone system inhibitors.
Epstein M; Reaven NL; Funk SE; McGaughey KJ; Oestreicher N; Knispel J
Am J Manag Care; 2015 Sep; 21(11 Suppl):S212-20. PubMed ID: 26619183
[TBL] [Abstract][Full Text] [Related]
20. Renin-angiotensin system inhibitors in hypertensive adults with non-diabetic CKD with or without proteinuria: a systematic review and meta-analysis of randomized trials.
Mishima E; Haruna Y; Arima H
Hypertens Res; 2019 Apr; 42(4):469-482. PubMed ID: 30948820
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]